When: Closing basis above $1,247 with volume >3.5M shares, MACD bullish re-cross with histogram turning positive, RSI >60

Then: Add back up to 75% of trimmed shares

When: 200 SMA ($1,040) tested in macro-driven selloff (election shock, policy event)

Then: Structural reload limited to 50% of trimmed shares; further adds require fundamental re-evaluation

BUY rating with 40-50% trim from current position; re-entry only at 1,167 (50 SMA) or below; closing-basis stop at upper Bollinger band (1,247) on expanding volume

• Current valuation: 40x trailing earnings, 24x forward earnings at 1,150 with $47 EPS estimate, 23.8x at lower Bollinger band (1,117) — not a margin of safety
• Re-entry zone at 1,167 (50 SMA) or 1,040 (200 SMA) required to address valuation; anything above 1,167 is still elevated
• Stop loss at 1,239 is only 3/4 ATR ($40) above current price (1,209) — too tight, will trigger on normal volatility or overnight gaps
• Recommended stop: upper Bollinger band at 1,247 on closing basis only, with one full ATR of room
• Structural risks independent of catalysts: $55B debt, $11B FCF matching $11B CapEx, inventory nearly quadrupled since 2022
• Key catalysts are priced in or low probability: Polymarket retatrutide approval at 3%, Q3 earnings faces 48% YoY bar
• After 20-30% trim: residual 70% position still exposed to 10-20% drawdown — incremental risk management, not contained
• MACD narrowing and volume contracting are valid warning signs; long-term trend still intact (200 SMA rising, price $169 above)
• Conservative approach: reduce to level where trend can work without risking firm capital if trend breaks

→ vs aggressive: A 20-30% trim leaves 70-80% of position exposed to the same 14-30% downside scenario — mathematically inconsistent with the bear case thesis

→ vs aggressive: Re-entry at 1,100-1,150 still prices in 23-24x forward earnings for a drug manufacturer — does not fix the valuation problem, just reduces it marginally

→ vs aggressive: Stop loss at 1,239 is 3/4 ATR above current price — will be triggered by normal daily swings ($40 ATR), overnight gaps, or news prints, causing whipsaw exits

→ vs aggressive: Core position retention for H2 catalyst optionality relies on binary events (Foundayo PDUFA at 3% probability) or tough comps (48% YoY bar) — not a basis for holding concentrated exposure

→ vs aggressive: Post-trim position still faces 10-20% drawdown on 70% of original size — not risk management, merely reduced risk

REDUCE 20% TO 25% of current position; retain core with $1,167 trend-risk stop (close below with expanding volume, MACD bearish cross, and RSI below 45 triggers additional 10% to 15% reduction); rebuild at $1,182-$1,196 support or on confirmed breakout above $1,247; deploy proceeds as one-third cash/short-duration debt, one-third diversified non-healthcare exposure, one-third staged LLY re-entry reserve.

• LLY currently valued at 25.7x forward earnings ($1,177 price / $47.07 EPS estimate); 40.6x trailing P/E uses different denominator ($1,209 / $29.77) and is not a forecast of compression
• Downside scenarios: $1,083 = 23x earnings, $1,412 = 30x earnings if $47.07 delivered
• Fundamental strength: 48% revenue growth, raised outlook, 54% operating margins, positive free cash flow, major therapeutic market leadership
• Net debt approximately $46 billion; material but not evidence of solvency crisis; FCF substantial despite CapEx expansion
• Technical: Stock above 10-day EMA, 50-day SMA, 200-day SMA; RSI neutral at 55.7; MACD above signal line with narrowing histogram but no bearish crossover
• RSI below 45 combined with MACD bearish cross and expanding volume would signal further reduction
• Re-entry zones: $1,182-$1,196 (demand zone) and $1,167 (deeper trend support)
• $1,247 is breakout-confirmation level, not automatic stop; requires daily close with expanding volume, stronger RSI, re-expanding MACD
• News sentiment 7.5/10 with low confidence (two retail-data sources unavailable)
• Aggressive exit ignores fundamental/technical strength; conservative 40-50% trim overcorrects when 20-25% achieves risk reduction
• Additional healthcare/GLP-1 exposure is not true diversification given regulatory and drug-pricing risks

→ vs aggressive: 7% to 15% upside versus 14% to 30% downside asymmetry was asserted rather than modeled; technical $1,270-$1,295 targets are only 5-7% above current price, not supporting the stated downside range

→ vs aggressive: P/E change treatment flawed: comparing 40.6x trailing multiple to ~25.5x forward multiple conflates different earnings denominators; $1,177 at $47.07 forward EPS equals 25x, not a compression forecast

→ vs aggressive: 58% earnings growth is not bearish in itself; earnings growth is the mechanism that supports the stock; the risk is delivery/miss, not mechanical EPS arrival

→ vs aggressive: Balance-sheet concerns are legitimate but overstated; $3.5B CapEx/FCF shortfall does not reconcile with reported figures; net debt of $46B is material but does not prove solvency crisis

→ vs aggressive: Technical analysis overstates bearish case: contracting volume consistent with profit-taking, not confirmed distribution; calling it definitive distribution top overstates evidence

→ vs conservative: $1,239 stop is only $30 above current price and less than one daily ATR; will be triggered by normal volatility and does not address overnight gap risk

→ vs conservative: Selling 40% to 50% is too defensive; if downside is 14% to 30%, correct inference is sizing according to portfolio risk, not automatic half liquidation

→ vs conservative: $1,040 re-entry target is too rigid; at $1,117 LLY would trade at 23.7x $47.07 estimate, at $1,040 at 22.1x; waiting for 200-day SMA does not magically make valuation safe

→ vs conservative: Position already oversized (more than 8-10% of liquid portfolio) warrants larger trim; if already near 60-75% of strategic benchmark weight, 20-25% reduction is more proportionate